Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
McKesson
Chubb
Cerilliant
Deloitte
Baxter
Boehringer Ingelheim
Covington
Johnson and Johnson

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,201,920

« Back to Dashboard

Which drugs does patent 7,201,920 protect, and when does it expire?

Patent 7,201,920 protects OXAYDO and is included in one NDA.

This patent has thirteen patent family members in six countries.
Summary for Patent: 7,201,920
Title:Methods and compositions for deterring abuse of opioid containing dosage forms
Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
Inventor(s): Kumar; Vijai (Morris Plains, NJ), Dixon; David (Woodside, NY), Tewari; Divya (Suffern, NY), Wadgaonkar; Dilip B. (Suffern, NY)
Assignee: Acura Pharmaceuticals, Inc. (Palatine, IL)
Application Number:10/723,654
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Drugs Protected by US Patent 7,201,920

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,201,920

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,822,489 Abuse deterrent compositions and methods of making same ➤ Sign Up
7,981,439 Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof ➤ Sign Up
8,101,630 Extended release opioid abuse deterrent compositions and methods of making same ➤ Sign Up
7,476,402 Methods and compositions for deterring abuse of opioid containing dosage forms ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
McKinsey
Federal Trade Commission
Chinese Patent Office
McKesson
Express Scripts
Citi
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.